Ignite Creation Date:
2024-05-06 @ 12:45 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01644617
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2012-07-17
Brief Title:
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite HDM Induced Allergic RhinitisRhinoconjunctivitis in Adults MK-8237-003P07627
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A Phase IIb Randomized Placebo-Controlled Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 Using an Environmental Exposure Chamber in Subjects With House Dust Induced Allergic RhinitisRhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the dose-related effectiveness the safety and the tolerability of MK-8237 compared to placebo in the treatment of house dust mite HDM-induced allergic rhinitisrhinoconjunctivitis in adults The primary hypothesis is that administration of MK-8237 compared to placebo results in dose-related improvement in the average total nasal symptom score TNSS determined during environmental exposure chamber EEC challenge
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-001855-38 | EUDRACT_NUMBER | None | None |
| 8237-003 | OTHER | Merck Registration Number | None |